Hi David
I’d simply note that trial size was very small. Also, I don’t like the way the endpoints were changed after the trial was finished, even if it was before data was unlocked.
Re first to market, drug developers always like to be in that position and it can be a major advantage provided you have the breathing space of a couple of years before any second- to- market treatment arrives.
But a combination of efficacy, price, ease of administration and side effect profile tend to ultimately decide which drug dominates the market, imo.
Hi David I’d simply note that trial size was very small. Also, I...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.97 |
Change
0.000(0.00%) |
Mkt cap ! $2.552B | |||
| Open | High | Low | Value | Volume |
| $19.96 | $19.97 | $19.69 | $4.156M | 209.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 246 | $19.88 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.99 | 512 | 1 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |